Journal of Shandong University (Health Sciences) ›› 2024, Vol. 62 ›› Issue (4): 92-100.doi: 10.6040/j.issn.1671-7554.0.2024.0118
• Clinical Medicine • Previous Articles
LIU Wenzhu, LIU Fuchen
CLC Number:
[1] Cortes CJ, La Spada AR. X-linked spinal and bulbar muscular atrophy: from clinical genetic features and molecular pathology to mechanisms underlying disease toxicity[J]. Adv Exp Med Biol, 2018, 1049: 103-133. doi: 10.1007/978-3-319-71779-1_5. [2] Borgia D, Malena A, Spinazzi M, et al. Increased mitophagy in the skeletal muscle of spinal and bulbar muscular atrophy patients[J]. Hum Mol Genet, 2017, 26(6): 1087-1103. [3] Feng X, Luo S, Lu B. Conformation polymorphism of polyglutamine proteins[J]. Trends Biochem Sci, 2018, 43(6): 424-435. [4] Minakawa EN, Nagai Y. Protein aggregation inhibitors as disease-modifying therapies for polyglutamine diseases[J]. Front Neurosci, 2021, 15: 621996. doi: 10.3389/fnins.2021.621996. [5] Giorgetti E, Lieberman AP. Polyglutamine androgen receptor-mediated neuromuscular disease[J]. Cell Mol Life Sci, 2016, 73(21): 3991-3999. [6] Querin G, Bertolin C, Da RE, et al. Non-neural phenotype of spinal and bulbar muscular atrophy: results from a large cohort of Italian patients[J]. J Neurol Neurosurg Psychiatry, 2016, 87(8): 810-816. [7] Fratta P, Nirmalananthan N, Masset L, et al. Correlation of clinical and molecular features in spinal bulbar muscular atrophy[J]. Neurology, 2014, 82(23): 2077-2084. [8] Hashizume A, Banno H, Katsuno M, et al. Quantitative assessment of swallowing dysfunction in patients with spinal and bulbar muscular atrophy[J]. Intern Med, 2017, 56(23): 3159-3165. [9] Suzuki K, Katsuno M, Banno H, et al. The profile of motor unit number estimation(MUNE)in spinal and bulbar muscular atrophy[J]. J Neurol Neurosurg Psychiatry, 2010, 81(5): 567-571. [10] Harding AE, Thomas PK, Baraitser M, et al. X-linked recessive bulbospinal neuronopathy: a report of ten cases[J]. J Neurol Neurosurg Psychiatry, 1982, 45(11): 1012-1019. [11] Sobue G, Hashizume Y, Mukai E, et al. X-linked recessive bulbospinal neuronopathy. A clinicopathological study[J]. Brain, 1989,112( Pt 1): 209-232. [12] Minakawa EN, Popiel HA, Tada M, et al. Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation[J]. Brain, 2020,143(6): 1811-1825. [13] Du ZW, Chen H, Liu H, et al. Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells[J]. Nat Commun, 2015, 6: 6626. doi: 10.1038/ncomms7626. [14] Giandomenico SL, Sutcliffe M,Lancaster MA.Generation and long-term culture of advanced cerebral organoids for studying later stages of neural development[J]. Nat Protoc, 2021, 16(2): 579-602. [15] Wang D, Zhang R, Wang Y, et al. Establishment of an induced pluripotent stem cell(iPSC)line(INNDSUi001-A)from a healthy female Chinese Han[J]. Stem Cell Res, 2022, 62: 102819. doi: 10.1016/j.scr.2022.102819. [16] Jamal A. Induced pluripotent stem cells(iPSCs): where are we and where are we heading?[J]. Cell Mol Biol(Noisy-le-grand), 2023, 69(11): 76-80. [17] Sato M, Takizawa H, Nakamura A, et al. Application of urine-derived stem cells to cellular modeling in neuromuscular and neurodegenerative diseases[J]. Front Mol Neurosci, 2019, 12: 297. doi: 10.3389/fnmol.2019.00297. [18] Petazzi P, Menendez P, Sevilla A. CRISPR/Cas9-mediated gene knockout and knockin human iPSCs[J]. Methods Mol Biol, 2022, 2454: 559-574. doi:10.1007/7651_2020_337. [19] Fernandez-Guasti A, Kruijver FP, Fodor M, et al. Sex differences in the distribution of androgen receptors in the human hypothalamus[J]. J Comp Neurol, 2000, 425(3): 422-435. [20] Li M, Sobue G, Doyu M, et al. Primary sensory neurons in X-linked recessive bulbospinal neuropathy: histopathology and androgen receptor gene expression[J]. Muscle Nerve, 1995,18(3): 301-308. [21] Ward PJ, Davey RA, Zajac JD, et al. Neuronal androgen receptor is required for activity dependent enhancement of peripheral nerve regeneration[J]. Dev Neurobiol, 2021, 81(4): 411-423. [22] Kumar R. Role of androgen receptor polyQ chain elongation in Kennedy's disease and use of natural osmolytes as potential therapeutic targets[J]. IUBMB Life, 2012, 64(11): 879-884. [23] Mazzini L, Gelati M, Profico DC, et al. Human neural stem cell transplantation in ALS: initial results from a phase I trial[J]. J Transl Med, 2015,13: 17. doi: 10.1186/s12967-014-0371-2. [24] Tadesse T, Gearing M, Senitzer D, et al. Analysis of graft survival in a trial of stem cell transplant in ALS[J]. Ann Clin Transl Neurol, 2014, 1(11): 900-908. [25] Glass JD, Hertzberg VS, Boulis NM, et al. Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials[J]. Neurology, 2016, 87(4): 392-400. |
[1] | CHEN Wenbiao, YU Xiangqi, DAI Yong. Different expressions of novel microRNAs of iPSCs from Alport syndrome [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(9): 80-85. |
[2] | ZHANG Wen-hua, WU Cheng-yuan, LI Xin-gang, XU Shu-jun, LI Gang, JIANG Yu-quan, ZHOU Mao-de, LIU Meng . Gene therapy for amyotrophic lateral sclerosis in a mouse model using a human glial cell linederived neurotrophic factor [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(11): 25-29. |
|